Those who have the possibility of developing chemotherapy-induced peripheral neurotoxicity
Conditions
Interventions
To measure the sural nerve sensory conduction verocity (SNCV) and sensory action potential (SNAP) by the point-of-care nerve conduction device (NC-stat) at each chemotherapy cycle
Sponsors
Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Adult patients who are going to have chemotherapy including oxaliplatin, paclitaxel or docetaxel are included. All patients will have written informed consent.
Exclusion criteria
Exclusion criteria: Patients with pre-existing neuropathy, such as diabetes mellitus, alcoholic abuse or central nervous system metastasis are excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of the point-of-care nerve conduction studies of those who have the possibility of developing CIPN, with the time course and extent of CIPN of them | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlation of the quantitative assesment of CIPN through the point-of-care nerve conduction device (NC-stat) with the quantitative assesment of CIPN through NCI-CTCAE ver4.0 | — |
Countries
Japan
Contacts
Public ContactAyumu Matsuoka
Nagoya University Hospital Department of Clinical Oncology and Chemotherapy
Outcome results
None listed